As of March 23, 2026, Artiva Biotherapeutics's top three insider holders are Corp. Gc (TenPercentOwner, 4.57Mn shares), Fred Aslan (President And Ceo, 1.56Mn shares), Yong-Jun Huh (Director, 1.26Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Corp. Gc | 3,306,900 | 1,260,512 | 22 Jul, 2024 | |
| Fred Aslan | President And Ceo | 1,562,198 | 0 | 18 Feb, 2026 |
| Yong-Jun Huh | 0 | 1,260,512 | 22 Jul, 2024 | |
| Partners Vi, Llc 5Am | 0 | 1,182,054 | 24 Jul, 2024 | |
| Capital Management, L.P. Ra | 0 | 826,832 | 24 Jul, 2024 | |
| Jennifer Bush | Coo, Clo, Secy, Compliance Off | 346,710 | 0 | 18 Feb, 2026 |
| Christopher Horan | Chief Tech Operations Officer | 300,452 | 0 | 18 Feb, 2026 |
| Thad Allen Huston | Chief Financial Officer | 220,000 | 0 | 10 Mar, 2026 |
| Biomedical Innovation Master Investors (Cayman) I L.P. Wellington | 194,108 | 0 | 22 Jul, 2024 | |
| Subhashis Banerjee | Chief Medical Officer | 152,000 | 0 | 18 Feb, 2026 |
| Heather Raymon | Svp, Research And Development | 151,323 | 0 | 18 Feb, 2026 |
| Neha Krishnamohan | Chief Financial Officer | 99,356 | 0 | 17 Nov, 2025 |
| Thorsten Graef | Chief Medical Officer | 80,000 | 0 | 27 Feb, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 10 Mar, 2026 | Thad Allen Huston | Common Stock | A | 220,000 | $0.00 | 220,000 | D | A |
| 18 Feb, 2026 | Elaine K. Sorg | Director Stock Option (Right to Buy) | A | 27,500 | $0.00 | 27,500 | D | A |
| 15 Feb, 2026 | Heather Raymon | Common Stock | A | 46,000 | $0.00 | 152,844 | D | A |
| 15 Feb, 2026 | Subhashis Banerjee | Common Stock | A | 102,000 | $0.00 | 152,000 | D | A |
| 15 Feb, 2026 | Christopher Horan | Common Stock | A | 117,300 | $0.00 | 302,639 | D | A |
| 15 Feb, 2026 | Jennifer Bush | Common Stock | A | 117,300 | $0.00 | 350,225 | D | A |
| 15 Feb, 2026 | Fred Aslan | Common Stock | A | 366,850 | $0.00 | 1,576,798 | D | A |
| 15 Feb, 2026 | Jennifer Bush | Common Stock | D | 3,515 | $4.00 | 346,710 | D | F |
| 15 Feb, 2026 | Fred Aslan | Common Stock | D | 14,600 | $4.00 | 1,562,198 | D | F |
| 15 Feb, 2026 | Christopher Horan | Common Stock | D | 2,187 | $4.00 | 300,452 | D | F |
| 15 Feb, 2026 | Heather Raymon | Common Stock | D | 1,521 | $4.00 | 151,323 | D | F |
| 15 Dec, 2025 | Fred Aslan | Common Stock | D | 3,187 | $6.00 | 1,209,948 | D | S |
| 12 Dec, 2025 | Christopher Horan | Common Stock | A | 107,156 | $0.00 | 185,339 | D | A |
| 12 Dec, 2025 | Heather Raymon | Common Stock | A | 67,253 | $0.00 | 106,844 | D | A |
| 12 Dec, 2025 | Fred Aslan | Common Stock | A | 869,136 | $0.00 | 1,213,135 | D | A |
| 12 Dec, 2025 | Jennifer Bush | Common Stock | A | 84,877 | $0.00 | 232,925 | D | A |
| 12 Dec, 2025 | Jennifer Bush | Employee Stock Option (Right to Buy) | D | 41,039 | - | 0 | D | D |
| 12 Dec, 2025 | Heather Raymon | Employee Stock Option (Right to Buy) | D | 18,239 | - | 0 | D | D |
| 12 Dec, 2025 | Fred Aslan | Employee Stock Option (Right to Buy) | D | 100,577 | - | 0 | D | D |
| 12 Dec, 2025 | Christopher Horan | Employee Stock Option (Right to Buy) | D | 77,519 | - | 0 | D | D |